Enabling catalytic and quantitative N- and C-terminal protein labelling
Lead Research Organisation:
University of Leeds
Department Name: Sch of Chemistry
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Michael Webb (Principal Investigator) |
Publications
Witkowska D
(2018)
Analysis of substrate binding in individual active sites of bifunctional human ATIC.
in Biochimica et biophysica acta. Proteins and proteomics
| Description | In this short (3 month) pathfinder project we aimed to develop a protein labelling technology which we had developed within the group. Catalytic and quantitative ways to modify proteins are of interest both for commercial applications and for use in academia. Within the project we carried out both a market analysis for our proposed technology and key proof-of-principle experiments. The proof-of-principle experiments were successful and supported continued investigation of the approach. This is now continuing through a subsequent BBSRC follow-on fund award (BB/R005540/1) which is ongoing. The initial commercial analysis enabled us to identify to identify a potential SME partner for the technology with whom we are now working. |
| Exploitation Route | We have obtained further funding (BB/R005540/1) to develop the initial findings from this pathfinder award into a commercialisable technology. |
| Sectors | Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
| Description | The technology developed through this proposal is now being used in industrial collaborations with existing and prospective non-academic research partners. Details of these collaborations are currently confidential. |
| First Year Of Impact | 2020 |
| Sector | Pharmaceuticals and Medical Biotechnology |
| Impact Types | Economic |
| Description | BBSRC follow-on fund |
| Amount | £250,000 (GBP) |
| Funding ID | BB/R005540/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 09/2019 |
| Description | Multivalent display of sugar antigens via site selective enzymatic modification of cholera toxin |
| Amount | £112,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | 10/2020 |
| End | 09/2024 |
| Description | Sortase conjugate vaccines |
| Amount | £39,288 (GBP) |
| Organisation | University of Leeds |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 10/2019 |
| End | 03/2020 |